Abstract
The literature review analyzes the data of 12-year clinical use of a fixed combination of 1% brinzolamide and 0.2 % brimonidine (BBFC) in the treatment of glaucoma and ocular hypertension. This drug is an alternative for patients with systemic contraindications in the form of broncho-obstructive syndrome and cardiovascular pathology. The monotherapy BBFC hypotensive effect is 30 % of the IOP initial level and corresponds to that of brinzolamide/brimonidine non-fixed combination. Switching patients with glaucoma and ocular hypertension from monotherapy with brinzolamide or brimonidine to BBFC is accompanied by an additional hypotensive effect at the of 13% of the initial IOP. BBFC has a good additional hypotensive effect in combination with drugs of other pharmaceutical groups, and also effectively relieves the hypertension after laser capsulotomy, intravitreal anti-VEGF injections and phacoemulsification. The most common BBFC ophthalmological adverse effects are conjunctival hyperemia, conjunctivitis, allergic reactions and eye discomfort with a frequency of about 10–20 %.

This publication has 54 references indexed in Scilit: